Remarkable advances have been made in the treatment of advanced NSCLC with molecularly targeted EGFR-TKIs, yet patients are highly susceptible to drug resistance (Tan et al., 2017; Dong et al., 2018). This evidence concerns the gene EGFR and non-small cell lung carcinoma.